Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alicia Tosoni

Showing results (81-90 of 105) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2006
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO studyAlba A Brandes, Alicia Tosoni, Giovanna Cavallo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patientsAlba A Brandes, Enrico Franceschi, Alicia Tosoni, et al.
Anticancer Research|March 10, 2015
The effect of re-operation on survival in patients with recurrent glioblastomaEnrico Franceschi, Marco Bartolotti, Alicia Tosoni, et al.
Expert Review of Anticancer Therapy|July 14, 2025
Emerging strategies and advances in the management of sinonasal carcinomaAlicia Tosoni, Maria Pia Foschini, Ernesto Pasquini, et al.
Future Oncology (London, England)|May 10, 2018
Temozolomide rechallenge in recurrent glioblastoma: when is it useful?Enrico Franceschi, Giuseppe Lamberti, Michela Visani, et al.
Oncotarget|September 15, 2017
Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II studyAlba A Brandes, Gaetano Finocchiaro, Vittorina Zagonel, et al.
Pathology, Research and Practice|August 20, 2024
TP53 mutations and survival in patients with histologically defined Glioblastoma, IDH-wildtypeVincenzo Di Nunno, Lidia Gatto, Alicia Tosoni, et al.
Journal of Neuro-Oncology|June 27, 2022
Machine learning in neuro-oncology: toward novel development fieldsVincenzo Di Nunno, Mario Fordellone, Giuseppe Minniti, et al.
Oral Oncology|August 10, 2025
The role of systemic therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma progressed to immunotherapy: A systematic review and meta analysisAlicia Tosoni, Vincenzo Di Nunno, Andrea Carlini, et al.
Journal of Neuro-Oncology|November 5, 2014
Post progression survival in glioblastoma: where are we?Enrico Franceschi, Mario Ermani, Stefania Bartolini, et al.
Pageof 11

Showing results (81-90 of 105) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2006
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO studyAlba A Brandes, Alicia Tosoni, Giovanna Cavallo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patientsAlba A Brandes, Enrico Franceschi, Alicia Tosoni, et al.
Anticancer Research|March 10, 2015
The effect of re-operation on survival in patients with recurrent glioblastomaEnrico Franceschi, Marco Bartolotti, Alicia Tosoni, et al.
Expert Review of Anticancer Therapy|July 14, 2025
Emerging strategies and advances in the management of sinonasal carcinomaAlicia Tosoni, Maria Pia Foschini, Ernesto Pasquini, et al.
Future Oncology (London, England)|May 10, 2018
Temozolomide rechallenge in recurrent glioblastoma: when is it useful?Enrico Franceschi, Giuseppe Lamberti, Michela Visani, et al.
Oncotarget|September 15, 2017
Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II studyAlba A Brandes, Gaetano Finocchiaro, Vittorina Zagonel, et al.
Pathology, Research and Practice|August 20, 2024
TP53 mutations and survival in patients with histologically defined Glioblastoma, IDH-wildtypeVincenzo Di Nunno, Lidia Gatto, Alicia Tosoni, et al.
Journal of Neuro-Oncology|June 27, 2022
Machine learning in neuro-oncology: toward novel development fieldsVincenzo Di Nunno, Mario Fordellone, Giuseppe Minniti, et al.
Oral Oncology|August 10, 2025
The role of systemic therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma progressed to immunotherapy: A systematic review and meta analysisAlicia Tosoni, Vincenzo Di Nunno, Andrea Carlini, et al.
Journal of Neuro-Oncology|November 5, 2014
Post progression survival in glioblastoma: where are we?Enrico Franceschi, Mario Ermani, Stefania Bartolini, et al.
Pageof 11